Coronary Syndrome
📧 Sign up to get email alerts when something new happens for Coronary Syndrome.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2010-01-26EMA Withdrawn: Clopidogrel BMS (clopidogrel (as hydrogen sulfate)) — Bristol-Myers Squibb Pharma EEIG
The EMA information indicates that the clopidogrel BMS product (clopidogrel as hydrogen sulfate) has been withdrawn from the market.
-
EMA withdrawal · 2009-04-23EMA Application withdrawn: Clopidogrel Teva Pharma (clopidogrel) — Teva Pharma B.V.
The EMA application for Clopidogrel Teva Pharma (clopidogrel) has been withdrawn.
-
EMA withdrawal · 2009-04-23Teva Pharma B.V. withdraws its marketing authorisation application for Clopidogrel Teva Pharma (clopidogrel hydrobromide)
Teva Pharma B.V. has withdrawn its marketing authorisation application for Clopidogrel Teva Pharma (clopidogrel hydrobromide).
-
EMA withdrawal · 2008-05-27EMA Application withdrawn: DuoCover (clopidogrel;acetylsalicylic acid) — Bristol Myers Squibb Pharma EEIG
EMA withdrew the application for DuoCover (clopidogrel and acetylsalicylic acid) from Bristol Myers Squibb Pharma EEIG.
-
EMA withdrawal · 2008-05-27EMA Application withdrawn: DuoPlavin (clopidogrel;acetylsalicylic acid) — Sanofi Pharma Bristol-Myers Squibb
EMA withdrew the application for DuoPlavin (clopidogrel and acetylsalicylic acid) by Sanofi Pharma Bristol-Myers Squibb.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.